Takeda signs deal with Sosei Heptares worth $1.2 billion

pharmafile | August 6, 2019 | News story | Manufacturing and Production GPCR, Sosei Heptares, Takeda, pharma, sosei 

Takeda has entered into a partnership with Sosei Heptares to develop drugs that modulate G protein-coupled receptor (GPCR) targets.

The agreement will see Takeda pay $26 million upfront and up to $1.2 billion in milestone payments. Sosei is also eligible to receive royalties on net sales of any products that result from the partnership between the two Japanese firms.

In signing the deal Takeda joins a group of big pharma firms who have partnered with Sosei over GCPRs including Genentech, Pfizer, AstraZeneca, Allergan, Novartis, and Daiichi-Sankyo.

Initially, Sosei will apply its GCPR targeted drug design capabilitieis towards gastrointestinal targets, chosen by Takeda, who are interested in treating gut inflammation and motility disorders. However the agreement provides scope to expand into other therapeutic areas.

Dr. Malcolm Weir, Executive VP and Chief R&D Officer of Sosei Heptares, said: “Takeda and Sosei Heptares have enjoyed a strong relationship over the years, with its venture arm having been an early investor in Heptares.”

Shinichi Tamura, Chairman, President and CEO of Sosei Heptares, added: “Sosei Heptares, like Takeda, has a proud heritage in Japan. This imbues both companies with a strong set of values and a powerful work ethic to create new medicines for patients in need around the world and in doing so build a successful, global company. We believe this new partnership is another step forward for Sosei Heptares and we are looking forward to working together on this exciting new collaboration.”

Louis Goss

Related Content

FDA grants Priority Review for Takeda’s cTTP treatment

Japanese biopharmaceutical company Takeda has announced that the US Food and Drug Administration (FDA) has …


Takeda collaboration to optimise biopharmaceutical manufacturing announced

A 36-month joint project between Takeda’s manufacturing site in Vienna, the Research Center Pharmaceutical Engineering …

Pfizer sign

Delayed Pfizer vaccine dose gives 3.5 times more immunity, study shows

The Pfizer-BioNTech COVID-19 vaccine is around three and a half times more effective when dosed …

Latest content